Eli Lilly and Company announced the U.S. FDA approved EBGLYSS, a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds with moderate-to-severe atopic dermatitis that is not well controlled despite treatment with topical prescription therapies. Eczema inflammation under the skin can lead to symptoms seen and felt on the outside. EBGLYSS works by targeting eczema inflammation throughout the body that can lead to dry, itchy and irritated skin.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Moderna, Halliburton downgraded: Wall Street’s top analyst calls
- Eli Lilly price target raised to $1,100 from $1,050 at JPMorgan
- Eli Lilly resumed with a Buy at Citi
- Roche obesity pill tied to high rates of nausea in ST study, Bloomberg says
- Eli Lilly announces $1B expansion of Ireland manufacturing site
